Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 80425-0535

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 80425-0535). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Rizatriptan Benzoate Odt 10mg #18 (Rizatriptan Benzoate Odt 10mg 80425 0535 01)

Rizatriptan Benzoate Odt 10mg #18 (Rizatriptan Benzoate Odt 10mg 80425 0535 01)
Label for Rizatriptan Benzoate ODT 10 mg tablet by Advanced Rx of Tennessee, LLC. The label includes comparison to MAXALT MLT, source NDC, lot number with expiration date 12/31/2027, and notes the product is prescription only. Storage instructions specify 20° to 25°C.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose. The graph compares placebo, Rizatriptan Benzoate 5 mg tablets, and Rizatriptan Benzoate 10 mg tablets based on pooled data from four outpatient studies, illustrating treatment response over time.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)
A Kaplan-Meier plot showing the estimated probability over 24 hours that patients will take a second dose of Rizatriptan Benzoate tablets or other migraine medication after an initial study dose. The graph compares placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg tablets, illustrating different rates of medication use over time following the first dose.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose comparing placebo, Rizatriptan Benzoate orally disintegrating tablets 5 mg, and 10 mg. The x-axis represents hours post-dose up to 2 hours, and the y-axis shows the estimated probability of response from 0% to 100%. The 10 mg dose shows the highest probability, followed by 5 mg and placebo.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)
A Kaplan-Meier plot showing the estimated probability over 24 hours that patients take a second dose of Rizatriptan Benzoate orally disintegrating tablets (5 mg and 10 mg) or placebo for migraine rescue. The x-axis represents hours post-dose, and the y-axis shows the estimated probability of taking medication for rescue, rising over time for each treatment group.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
A line graph showing the observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7. The x-axis represents hours post stage 2 dose (0.5 to 2.0 hours), and the y-axis represents the percentage (with 95% confidence interval) of patients reporting no headache pain. Two lines compare Rizatriptan Benzoate OD Tablets and placebo, with Rizatriptan showing a higher percentage over time.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure diagram of Rizatriptan Benzoate showing the molecular arrangement of its atoms and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.